GT Medical Technologies Announces New Clinical Evidence Supporting GammaTile® for Recurrent Brain Metastases

GT Medical Technologies today announced the publication of new data in the Journal of Neuro-Oncology demonstrating the effectiveness of GammaTile® therapy for patients with recurrent brain metastases following prior surgery and external beam radiation therapy (EBRT). The study, conducted at MD Anderson Cancer Center, highlights GammaTile’s ability to achieve durable local tumor control with low toxicity in a challenging patient population.

GammaTile is a bioabsorbable collagen implant embedded with cesium-131 radiation seeds, designed to deliver targeted radiation directly to the resection cavity at the time of surgery. By closing the traditional treatment gap between surgery and post-operative radiation, GammaTile provides immediate, continuous therapy where recurrence risk is highest.

The study evaluated 31 patients with 38 previously irradiated tumors who underwent salvage resection followed by GammaTile implantation. At one year, local control was achieved in approximately 87% of cases overall, and 94% of cases with gross total resection. Symptomatic radiation toxicity was low, observed in only 8% of patients.

These outcomes compare favorably to historical benchmarks. Resection alone typically results in recurrence rates of up to 40% within a year, while resection with repeat stereotactic radiosurgery (SRS) achieves 71–75% local control at one year but with higher toxicity risks. By contrast, GammaTile has demonstrated 80–100% local control at one year across multiple studies, consistently with lower toxicity.

“This study reinforces the growing body of evidence showing that GammaTile can provide meaningful local control even in patients previously treated with radiation,” said Michael Garcia, MD, MS, Chief Medical Officer of GT Medical Technologies. “For patients living longer with metastatic disease due to advances in systemic therapy, controlling brain tumor recurrence locally is critical—and GammaTile offers a safe, effective option where other treatments may be limited.”

This is the fourth peer-reviewed publication supporting GammaTile in recurrent brain metastases. In addition, recent research from the Miami Cancer Institute showed that GammaTile delivers higher therapeutic dose to the surgical cavity while reducing radiation exposure to surrounding brain tissue compared to stereotactic radiation. Together, these findings underscore GammaTile’s unique dosimetric advantages and its potential to redefine the standard of care for recurrent intracranial metastases.